TW201922241A - 美羅培南與法硼巴坦的組合之用途 - Google Patents

美羅培南與法硼巴坦的組合之用途 Download PDF

Info

Publication number
TW201922241A
TW201922241A TW107134824A TW107134824A TW201922241A TW 201922241 A TW201922241 A TW 201922241A TW 107134824 A TW107134824 A TW 107134824A TW 107134824 A TW107134824 A TW 107134824A TW 201922241 A TW201922241 A TW 201922241A
Authority
TW
Taiwan
Prior art keywords
subject
meropenem
dose
administered
farborbactam
Prior art date
Application number
TW107134824A
Other languages
English (en)
Chinese (zh)
Inventor
伊麗莎白 亞利山大
傑夫 盧蒂
麥可 Ｎ. 達德利
Original Assignee
美商萊姆派克斯製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65994826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201922241(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商萊姆派克斯製藥公司 filed Critical 美商萊姆派克斯製藥公司
Publication of TW201922241A publication Critical patent/TW201922241A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW107134824A 2017-10-03 2018-10-02 美羅培南與法硼巴坦的組合之用途 TW201922241A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762567702P 2017-10-03 2017-10-03
US62/567,702 2017-10-03
US201862657402P 2018-04-13 2018-04-13
US62/657,402 2018-04-13

Publications (1)

Publication Number Publication Date
TW201922241A true TW201922241A (zh) 2019-06-16

Family

ID=65994826

Family Applications (2)

Application Number Title Priority Date Filing Date
TW107134824A TW201922241A (zh) 2017-10-03 2018-10-02 美羅培南與法硼巴坦的組合之用途
TW112133851A TW202400146A (zh) 2017-10-03 2018-10-02 美羅培南與法硼巴坦的組合之用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW112133851A TW202400146A (zh) 2017-10-03 2018-10-02 美羅培南與法硼巴坦的組合之用途

Country Status (16)

Country Link
US (3) US11376237B2 (https=)
EP (1) EP3691652A4 (https=)
JP (1) JP2020536092A (https=)
KR (1) KR20200066664A (https=)
CN (1) CN111432821A (https=)
AU (1) AU2018345317B2 (https=)
BR (1) BR112020006658A2 (https=)
CA (1) CA3078238A1 (https=)
CL (1) CL2020000892A1 (https=)
JO (1) JOP20200075A1 (https=)
MX (1) MX2020003670A (https=)
MY (1) MY200934A (https=)
PH (1) PH12020550249A1 (https=)
SG (1) SG11202003009QA (https=)
TW (2) TW201922241A (https=)
WO (1) WO2019070591A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11376237B2 (en) 2017-10-03 2022-07-05 Melinta Subsidiary Corp. Methods of treating bacterial infections
EP4313033A4 (en) * 2021-03-24 2025-04-23 Trustees Of Tufts College BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101912363A (zh) 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
CA2807546C (en) 2010-08-10 2022-08-23 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN102188395B (zh) 2011-04-29 2012-12-05 石药集团中诺药业（石家庄）有限公司 一种更稳定的美罗培南注射剂及其制备方法
CN102335136B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种供注射用美罗培南药物组合物及其制备方法
CN102335137B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种含美罗培南的药物组合物
CN102525961B (zh) 2012-01-17 2013-02-13 山东罗欣药业股份有限公司 美罗培南组合物注射用粉针剂
US10561675B2 (en) * 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN103570718B (zh) 2012-07-31 2016-06-29 深圳市海滨制药有限公司 一种美罗培南原料药、其制备方法及包含其的药物组合物
RU2675847C2 (ru) 2013-05-28 2018-12-25 Морфохем Акциенгезельшафт Фюр Комбинаторише Хеми Комбинированные терапевтические средства, содержащие оксазолидинон-хинолоны, предназначенные для лечения бактериальных инфекций
WO2016172208A1 (en) 2015-04-24 2016-10-27 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
CN108289896B (zh) 2015-07-09 2022-03-01 华盛顿大学 抗菌药物组合的组合物和使用方法
US9949995B2 (en) 2015-09-04 2018-04-24 Case Western Reserve University Compositions and methods of treating of bacterial infections with β-lactamase inhibitors
JP7436206B2 (ja) 2017-01-09 2024-02-21 レンペックス・ファーマシューティカルズ・インコーポレイテッド 細菌感染症を処置する方法
US11376237B2 (en) * 2017-10-03 2022-07-05 Melinta Subsidiary Corp. Methods of treating bacterial infections

Also Published As

Publication number Publication date
AU2018345317B2 (en) 2024-10-24
CA3078238A1 (en) 2019-04-11
EP3691652A1 (en) 2020-08-12
US11376237B2 (en) 2022-07-05
JP2020536092A (ja) 2020-12-10
US20200297695A1 (en) 2020-09-24
JOP20200075A1 (ar) 2020-04-30
AU2018345317A1 (en) 2020-05-07
PH12020550249A1 (en) 2021-02-15
KR20200066664A (ko) 2020-06-10
EP3691652A4 (en) 2021-07-07
MY200934A (en) 2024-01-24
US20220288024A1 (en) 2022-09-15
CN111432821A (zh) 2020-07-17
CL2020000892A1 (es) 2020-10-23
BR112020006658A2 (pt) 2020-09-24
SG11202003009QA (en) 2020-04-29
WO2019070591A1 (en) 2019-04-11
US12533342B2 (en) 2026-01-27
MX2020003670A (es) 2020-08-03
US20260102374A1 (en) 2026-04-16
TW202400146A (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
Willems et al. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics
US20260102374A1 (en) Methods of treating bacterial infections
JP2018514589A5 (https=)
WO2020043185A1 (zh) 氨基酸类营养素的应用以及包含它的药物组合物
US20210393666A1 (en) Methods and compositions for treating oral mucositis
TW200820995A (en) Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
CN103370066A (zh) 用于治疗癌症的包含威罗菲尼和干扰素的组合疗法
US20100144626A1 (en) Treatment of Multi-Drug Resistant Bacterial Infections
KR20250134233A (ko) β-락타마제 억제제를 함유하는 약제학적 조성물 및 이의 용도
US10329262B2 (en) Quinazolinone antibiotics
TW202106690A (zh) 皮膚型紅斑狼瘡之治療
US20080207644A1 (en) Therapeutic materials and methods
CA3071096A1 (en) Co-administration of minocycline and colistin to reduce acute kidney injury
TWI705814B (zh) 醫藥組成物及其用途
US20210052608A1 (en) Methods of treating bacterial infections with minocycline
RU2008108216A (ru) Фармацевтические дозированные формы и составы, содержащие лекозотан
WO2024073672A1 (en) Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
MX2015003810A (es) Metadoxina para usarse en el tratamiento de enfermedades hepaticas y formulaciones de liberacion prolongada de metadoxina.
CN110664799A (zh) 用于治疗脑缺血的药物组合物及其应用
US20090247498A1 (en) Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications